CA-H2O.AI
26.1.2021 17:21:12 CET | Business Wire | Press release
H2O.ai announces H2O AI Hybrid Cloud, an end-to-end AI platform that enables organizations to build rapidly, share, and use AI models and applications.
An innovative new platform, H2O AI Hybrid Cloud, empowers anyone to innovate and use AI to make better forecasts, streamline operations, reduce risk, and personalize customer experiences. It contains capabilities and automation across the entire data science lifecycle, including connecting to and preparing data, building and explaining models, deploying and operating models, and building and sharing AI applications.
“AI is central to AT&T’s mission to deliver wireless, broadband, and software-based video to our customers. We’ve deployed hundreds of AI models to support those products and services, such as to protect our customers by scoring transactions in real-time for the likelihood of fraud. Collaborating with H2O around their open source tools including H2O Wave and H2O AI Hybrid Cloud will let us expand those capabilities across AT&T.” – Mark Austin, Vice President of Data Science, AT&T
H2O AI Hybrid Cloud is deployed on Kubernetes, enabling customers to operate on any cloud, such as Microsoft Azure or on-premises infrastructure.
The platform features over 200 data connectors, automatic data visualization, automatic feature engineering, AutoML for tabular, time-series, text, image, and video data, and machine learning operations technology to help organizations govern and continuously improve models. H2O AI Hybrid Cloud is integrated with Snowflake, enabling data engineers to make AI models and score records using their preferred language -- SQL.
"It used to take large teams of expert data scientists months, or longer, to develop a single model, but today, with Snowflake’s extensibility capabilities and H2O's AutoML technology, data engineers can rapidly build and deploy their models and score records, all from within Snowflake using SQL." - Snowflake Director of Product Management, Torsten Grabs
The H2O AI Hybrid Cloud integrates with the recently released H2O Wave and is built for organizations that want to put AI into their business users’ hands. An open-source lightweight Python development framework, this platform makes it easy for developers, data scientists, and machine learning engineers to make sophisticated applications that leverage AI models.
“The future is no-touch, seamless, frictionless automation, supported by deep insights. Powered by H2O AI Hybrid Cloud, Arogya Mitra Sejati is bringing to life Arogya, a deep insights based automated supply chain platform - optimized for healthcare.” - Vijay Sarashetti, Cofounder and CTO, Arogya
H2O AI Hybrid Cloud also provides an AppStore, enabling organizations to publish and share the AI applications they build with H2O Wave. The AppStore deploys with a set of pre-built applications, such as Automatic Insights, Recommendations, and LIBOR, which organizations can use to put AI into production even faster.
“AI is transforming the world. Organizations are adopting AI at increasing rates and need holistic, open and automated platforms to make world-class AI models and applications rapidly. H2O AI Hybrid Cloud enables organizations to make AI for virtually any use case, streamline machine learning operations and democratize AI across the organization.” -Sri Ambati, CEO, H2O.ai
To meet hybrid and multi-cloud requirements for enterprises, Red Hat OpenShift will certify the platform early this year.
“Red Hat OpenShift, the industry’s leading enterprise-grade, fully-supported Kubernetes platform, is optimized for H2O Driverless AI and H2O Open Source, making it easier for customers to deploy and manage H2O.ai products across the hybrid cloud. We are working closely with H2O.ai as they seek to certify H2O AI Hybrid Cloud on OpenShift in order to continue building on this momentum.” - Joe Fernandes, Vice President and General Manager, Cloud Platforms, Red Hat
About H2O.ai
H2O.ai is a leading AI technology company that enables organizations to rapidly build world-class AI models and applications. We continue to reimagine what is possible with artificial intelligence and deliver new platforms and technologies to put responsible AI into the hands of more users.
Our vision is to democratize AI by making it easier for individuals to build and access world-class and responsible AI. To achieve this vision, we’re creating a culture of responsible and engaged makers: community, customers, partners, entrepreneurs, and our own “makers,” and we’re enabling them with the technology to “make.” H2O is a leading open-source data science and machine learning platform used by nearly half of the Fortune 500 and trusted by over 20,000 organizations and hundreds of thousands of data scientists around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005850/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
